The First of its Kind in the Plant-Based Space
This company’s revolutionary technology may change the dairy industry forever. Learn more.
pixel

NASDAQ:AYTU - Aytu Biopharma Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $9.50
  • Forecasted Upside: 61.02 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$5.90
▲ +1.17 (24.74%)

This chart shows the closing price for AYTU by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Aytu Biopharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AYTU and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AYTU

Analyst Price Target is $9.50
▲ +61.02% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Aytu Biopharma in the last 3 months. The average price target is $9.50, with a high forecast of $14.50 and a low forecast of $3.00. The average price target represents a 61.02% upside from the last price of $5.90.

This chart shows the closing price for AYTU for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart
A Ground-Floor Opportunity in the Dairy Free Space
This industry pioneer isn’t your average plant-based dairy company. Find out why.
pixel

Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in Aytu Biopharma. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/29/2019
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/28/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/26/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/24/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/23/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/23/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/22/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/21/2021

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/18/2021LADENBURG THALM/SH SHReiterated RatingBuy$14.50High
3/29/2021Cantor FitzgeraldInitiated CoverageOverweight$11.00Medium
8/6/2020HC WainwrightReiterated RatingBuy$3.00Medium
5/29/2020HC WainwrightInitiated CoverageBuy$3.00High
11/15/2019Northland SecuritiesInitiated CoverageBuy$5.00High
9/27/2019Northland SecuritiesSet Price TargetBuy$10.00Low
9/18/2019LADENBURG THALM/SH SHBoost Price Target$4.00 ➝ $4.75Medium
9/13/2019Northland SecuritiesSet Price TargetBuy$10.00Medium
7/30/2019Northland SecuritiesReiterated RatingBuy$10.00High
6/4/2019Northland SecuritiesReiterated RatingBuy$10.00High
5/14/2019Northland SecuritiesReiterated RatingBuy$10.00Medium
3/27/2019Northland SecuritiesReiterated RatingBuyMedium
3/19/2019Northland SecuritiesSet Price TargetBuy$10.00High
10/22/2018Northland SecuritiesInitiated CoverageOutperform$10.00Medium
7/6/2017HC WainwrightSet Price TargetBuy$3.00N/A
2/17/2017Taglich BrothersReiterated RatingSpeculative BuyN/A
9/29/2016HC WainwrightReiterated RatingBuy$9.00N/A
9/26/2016Rodman & RenshawInitiated CoverageBuy$9.00N/A
(Data available from 6/21/2016 forward)
Aytu Biopharma logo
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), cough and upper respiratory symptoms, insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension. It also offers ZolpiMist, an oral spray for the treatment of insomnia; and MiOXSYS, an in vitro diagnostic semen analysis test that is used in the measurement of static oxidation reduction potential in human semen. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. is based in Englewood, Colorado.
Read More

Today's Range

Now: $5.90
Low: $4.99
High: $5.90

50 Day Range

MA: $5.77
Low: $4.73
High: $7.06

52 Week Range

Now: $5.90
Low: $4.73
High: $17.00

Volume

192,778 shs

Average Volume

710,717 shs

Market Capitalization

$148.51 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Aytu Biopharma?

The following sell-side analysts have issued reports on Aytu Biopharma in the last year: Cantor Fitzgerald, HC Wainwright, LADENBURG THALM/SH SH, and Zacks Investment Research.
View the latest analyst ratings for AYTU.

What is the current price target for Aytu Biopharma?

3 Wall Street analysts have set twelve-month price targets for Aytu Biopharma in the last year. Their average twelve-month price target is $9.50, suggesting a possible upside of 100.8%. LADENBURG THALM/SH SH has the highest price target set, predicting AYTU will reach $14.50 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $3.00 for Aytu Biopharma in the next year.
View the latest price targets for AYTU.

What is the current consensus analyst rating for Aytu Biopharma?

Aytu Biopharma currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AYTU will outperform the market and that investors should add to their positions of Aytu Biopharma.
View the latest ratings for AYTU.

What other companies compete with Aytu Biopharma?

How do I contact Aytu Biopharma's investor relations team?

Aytu Biopharma's physical mailing address is 373 INVERNESS PARKWAY SUITE 206, ENGLEWOOD CO, 80112. The company's listed phone number is 720-437-6580 and its investor relations email address is [email protected] The official website for Aytu Biopharma is aytubio.com.

A Ground-Floor Opportunity in the Dairy Free Space
This industry pioneer isn’t your average plant-based dairy company. Find out why.
pixel